141 results on '"ROOBOL, A"'
Search Results
2. Prostate Specific Antigen and Prostate Cancer in Chinese Men Undergoing Initial Prostate Biopsies Compared with Western Cohorts
3. Do Treatment Differences between Arms Affect the Main Outcome of ERSPC Rotterdam?
4. A Critical Analysis of the Tumor Volume Threshold for Clinically Insignificant Prostate Cancer Using a Data Set of a Randomized Screening Trial
5. PREDICTING LOW-RISK PROSTATE CANCER FROM TRANSPERINEAL SATURATION BIOPSIES: MP80-16
6. PROPERTIES OF THE FOUR KALLIKREIN PANEL FOR PREDICTION OF PROSTATE BIOPSY OUTCOME IN MEN WITH HIGH PSA (10-25 NG /ML): MP39-09
7. ESTIMATING THE HARMS AND BENEFITS OF PROSTATE CANCER SCREENING: COMPARING COMMON CLINICAL PRACTICE TO RECOMMENDED GOOD PRACTICE: PD09-04
8. VALIDATION OF A RISK CALCULATOR PREDICTING BIOPSY OUTCOME IN PROSTATE CANCER TREATED WITH ACTIVE SURVEILLANCE: PD08-04
9. CORRELATION BETWEEN STAGE SHIFT AND DIFFERENCES IN MORTALITY BETWEEN THE TWO STUDY ARMS OF THE ERSPC.: PD09-01
10. Prostate Specific Antigen Velocity Does Not Aid Prostate Cancer Detection in Men With Prior Negative Biopsy
11. Do Anxiety and Distress Increase During Active Surveillance for Low Risk Prostate Cancer?
12. How Often is Biopsy Necessary in Patients with Prostate Cancer on Active Surveillance?
13. PD46-06 PSA BASED SCREENING FOR PROSTATE CANCER: STARTING TOO LATE AND NON-COMPLIANCE, LIMITING THE NUMBER OF SCREENING VISITS, NEGATIVELY AFFECT PC MORTALITY REDUCTION.
14. PD46-03 PROSTATE CANCER DETECTION AFTER THREE NEGATIVE SCREENS WITH A 4-YEAR INTERVAL. ERSPC ROTTERDAM
15. PD34-04 FREQUENCY OF PSA TESTING IN MEN ON ACTIVE SURVEILLANCE FOR PROSTATE CANCER.
16. A Framework for the Identification of Men at Increased Risk for Prostate Cancer
17. Defining Increased Future Risk for Prostate Cancer: Evidence From a Population Based Screening Cohort
18. OUTCOME IN MEN CONTINUING ACTIVE SURVEILLANCE DESPITE PROTOCOL ADVICE TO DISCONTINUE: MP62-10
19. THE ROTTERDAM PROSTATE CANCER RISK CALCULATOR: IMPROVED PREDICTION WITH MORE RELEVANT PRE-BIOPSY INFORMATION, NOW IN THE PALM OF YOUR HAND: PD19-03
20. Prediction of Indolent Prostate Cancer: Validation and Updating of a Prognostic Nomogram
21. A PREDICTION BASED ON LEVELS OF FOUR KALLIKREIN MARKERS IN BLOOD IMPROVES PREOPERATIVE PREDICTION OF INDOLENT VERSUS AGGRESSIVE PROSTATE CANCER IN RADICAL PROSTATECTOMY SPECIMENS: 2135
22. Prevalence, Treatment Modalities and Prognosis of Familial Prostate Cancer in a Screened Population
23. LIVING WITH UNTREATED PROSTATE CANCER: THE IMPACT OF ACTIVE SURVEILLANCE ON QUALITY OF LIFE: 996
24. PROSTATE CANCER DISEASE PROGRESSION AND MORTALITY AFTER RADICAL PROSTATECTOMY OR EXTERNAL BEAM RADIOTHERAPY: RESULTS FROM THE ERSPC, SECTION ROTTERDAM: 989
25. MP13-05 RISK STRATIFICATION BASED ON SIZE OF EQUIVOCAL PI-RADS LESIONS MAY SAFELY REDUCE THE NUMBER OF MRI-TARGETED BIOPSIES
26. Initial Prostate Specific Antigen 1.5 ng/ml or Greater in Men 50 Years Old or Younger Predicts Higher Prostate Cancer Risk
27. HEAD TO HEAD COMPARISON OF THE ERSPC RISK CALCULATOR AND ANN PROSTATACLASS IN 4685 PATIENTS FOR PROSTATE CANCER RISK ON BIOPSY: 1982
28. OUTCOMES OF MEN DIAGNOSED WITH SCREEN-DETECTED PROSTATE CANCER INITIALLY WITHHOLDING RADICAL TREATMENT: 124
29. PC DETECTION IN MEN WITH INITIAL PSA LEVELS < 3.0 NG/ML. DATA FROM ERSPC 1993- 2007.: 1792
30. SECONDARY ANALYSIS OF THE EUROPEAN RANDOMIZED STUDY OF SCREENING FOR PROSTATE CANCER (ERSPC) - EFFECT OF PROSTATE CANCER SCREENING ON THE DEVELOPMENT OF METASTASES AFTER ADJUSTMENT FOR NON-COMPLIANCE AND CONTAMINATION.: 648
31. ANXIETY AND DISTRESS DURING ACTIVE SURVEILLANCE FOR EARLY PROSTATE CANCER: A LONGITUDINAL ANALYSIS: 498
32. ANXIETY AND DISTRESS DURING ACTIVE SURVEILLANCE FOR EARLY PROSTATE CANCER: A LONGITUDINAL ANALYSIS: 498
33. COMPARISON OF SCREEN DETECTED AND CLINICALLY DIAGNOSED PROSTATE CANCER IN THE EUROPEAN RANDOMIZED STUDY OF SCREENING FOR PROSTATE CANCER, SECTION ROTTERDAM
34. 4-YEAR PROSTATE SPECIFIC ANTIGEN PROGRESSION AND DIAGNOSIS OF PROSTATE CANCER IN THE EUROPEAN RANDOMIZED STUDY OF SCREENING FOR PROSTATE CANCER, SECTION ROTTERDAM
35. MP13-05 RISK STRATIFICATION BASED ON SIZE OF EQUIVOCAL PI-RADS LESIONS MAY SAFELY REDUCE THE NUMBER OF MRI-TARGETED BIOPSIES
36. THE USE OF -2proPSA AND BPSA IN PROSTATE CANCER DETECTION: EXTERNAL CROSS-VALIDATION OF A PREDICTIVE MODEL: 2049
37. PROSTATE CANCER (PC) IN MEN PRESENTING WITH PSA <3.0 NG/ML – DETECTION AT RE-SCREENING AND AS INTERVAL CANCERS DURING A 12-YEAR PERIOD: 1881
38. THE CLINICAL IMPACT OF THE PSA ASSAY WHO CALIBRATION ON PROSTATE BIOPSY RATES AND PROSTATE CANCER DETECTION: 1757
39. VALUE OF PSA VELOCITY FOR PREDICTING BIOPSY OUTCOME IN PREVIOUSLY SCREENED MEN PARTICIPATING IN THE EUROPEAN RANDOMIZED STUDY OF PROSTATE CANCER SCREENING (ERSPC): 1756
40. OVERALL VERSUS DISEASE-SPECIFIC SURVIVAL OF SCREEN- DETECTED PROSTATE CANCER PATIENTS WHO WERE INITIALLY MANAGED EXPECTANTLY: 430
41. Reply by Authors
42. PROSTATE CANCER DETECTION IN THE PROSTATE SPECIFIC ANTIGEN RANGE OF 2.0 TO 3.9 NG/ML: VALUE OF PERCENT FREE PROSTATE SPECIFIC ANTIGEN ON TUMOR DETECTION AND TUMOR AGGRESSIVENESS
43. Editorial Comment
44. MP77-15 A MULTI-CENTRE RANDOMISED CONTROLLED TRIAL ASSESSING WHETHER MRI-TARGETED BIOPSY IS NON-INFERIOR TO STANDARD TRANS-RECTAL ULTRASOUND GUIDED BIOPSY FOR THE DIAGNOSIS OF CLINICALLY SIGNIFICANT PROSTATE CANCER IN MEN WITHOUT PRIOR BIOPSY - THE PRECISION STUDY: PROSTATE EVALUATION FOR CLINICALLY IMPORTANT DISEASE, SAMPLING USING IMAGE-GUIDANCE OR NOT? (NCT02380027)
45. MP57-05 PROSTATE CANCER SCREENING: RESULTS OF A UNIQUE COHORT AT 19 YEARS OF FOLLOW-UP
46. MP46-13 CLINICAL IMPACT OF INCLUDING THE 4KSCORE IN THE CRIBRIFORM-UPDATED ERSPC ROTTERDAM PROSTATE CANCER RISK CALCULATOR PREDICTING CLINICALLY SIGNIFICANT PROSTATE CANCER
47. MP40-04 THE IMPACT OF FALSE NEGATIVE PROSTATE SPECIFIC ANTIGEN- AND BIOPSY RESULTS IN PROSTATE CANCER SCREENING
48. PD23-09 MULTIVARIABLE RISK-STRATIFICATION IN A PRIMARY HEALTHCARE SETTING: REFERRAL RATE AND BIOPSY RESULTS FROM A UROLOGY OUTPATIENT CENTER.
49. PD20-02 CAN ACTIVE SURVEILLANCE REALLY REDUCE THE HARMS OF PSA TESTING, LIKE THE U.S. PREVENTATIVE SERVICES TASK FORCE CURRENTLY SUGGESTS? THE PRIAS-STUDY IMPLICATES CAUTION
50. MP12-01 CONSISTENT BIOPSY QUALITY AND GLEASON GRADING WITHIN THE GLOBAL ACTIVE SURVEILLANCE GLOBAL ACTION PLAN 3 INITIATIVE: A PREREQUISITE FOR FUTURE STUDIES
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.